Jiahui Chen

Jiahui Chen

Auto-generated profile, based on publicly available information

Jiahui Chen

Jiangsu Key Laboratory for Molecular and Medical Biotechnology, Cancer Institute, Department of Biochemistry, College of Life Science, Nanjing Normal University, Nanjing, P. R. China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
YLYan Liu
Yan Liu
JCJiahui Chen
Jiahui Chen
JTJia Tian
Jia Tian
YHYu Hao
Yu Hao
XMXinxing Ma
Xinxing Ma
LFLiangzhu Feng
Liangzhu Feng
Surgical resection is a primary treatment option for patients with triple-negative breast cancer (TNBC), but it is associated with a high rate of postoperative local and metastatic relapse. Although chimeric antigen receptor–engineered NK (CAR-NK) cell therapy can specifically recognize and eradicate tumor cells, its therapeutic potency toward TNBCs is markedly suppressed by the hostile tumor microenvironment, which restricts the infiltration, survival, and effector functions of CAR-NK cells inside tumor masses. In this study, HER1-overexpressing TNBC-targeted CAR-NK (HER1-CAR-NK) cells were genetically engineered with catalase to endow them with tolerance toward the high levels of oxidative stress and hypoxia inside TNBC tumors through the catalytic decomposition of hydrogen peroxide, which is a principle reactive oxygen species inside tumors, into O2. We refer to these cells as HER1-CAR-CAT-NK cells. Upon intratumoral fixation with an injectable alginate hydrogel, HER1-CAR-CAT-NK cells enabled sustained tumor hypoxia attenuation and exhibited markedly enhanced persistence and effector functions inside TNBC tumors. As a result, locoregional HER1-CAR-CAT-NK cell therapy not only inhibited the growth of local primary residual tumors but also elicited systemic antitumor activity to suppress the growth of distant tumors. This study highlights that genetic engineering of HER1-CAR-NK cells with catalase is a promising strategy to suppress the postoperative local and distant relapse of TNBC tumors.

17 June 2026
Verified
Other
Open access
YLYan Liu
Yan Liu
JCJiahui Chen
Jiahui Chen
JTJia Tian
Jia Tian
YHYu Hao
Yu Hao
XMXinxing Ma
Xinxing Ma
LFLiangzhu Feng
Liangzhu Feng
Figure S12. Individual tumor growth curves of parental MDA-MB-231 tumor-bearing mice subjected to different treatments (related to Figure 5B).

17 June 2026
Verified
Other
Open access
YLYan Liu
Yan Liu
JCJiahui Chen
Jiahui Chen
JTJia Tian
Jia Tian
YHYu Hao
Yu Hao
XMXinxing Ma
Xinxing Ma
LFLiangzhu Feng
Liangzhu Feng
Figure S13. Individual tumor growth curves of brain metastatic MDA-MB-231 tumor-bearing mice subjected to different treatments (related to Figure 5F).

17 June 2026
Verified
Other
Open access
YLYan Liu
Yan Liu
JCJiahui Chen
Jiahui Chen
JTJia Tian
Jia Tian
YHYu Hao
Yu Hao
XMXinxing Ma
Xinxing Ma
LFLiangzhu Feng
Liangzhu Feng
Figure S11. Semiquantitative statistical analysis of percentages of specific areas affected by pimonidazole based on the fluorescence images in Figure 4I. (***p < 0.001, **p < 0.01).

17 June 2026
Verified
Other
Open access
YLYan Liu
Yan Liu
JCJiahui Chen
Jiahui Chen
JTJia Tian
Jia Tian
YHYu Hao
Yu Hao
XMXinxing Ma
Xinxing Ma
LFLiangzhu Feng
Liangzhu Feng
Figure S2. HER1 expression levels in 293T cells, parental MDA-MB-231 cells, and brain metastatic MDA-MB-231 cells via real-time PCR (A), western blotting (B) and flow cytometry (C). (***p < 0.001).